Cancer treatment and research communications最新文献

{"title":"Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort study","authors":"Constance Bordet ,&nbsp;Mahmoud Zureik ,&nbsp;Yoann Zelmat ,&nbsp;Margaux Lafaurie ,&nbsp;Maryse Lapeyre-Mestre ,&nbsp;Agnès Sommet ,&nbsp;Julien Mazieres ,&nbsp;Fabien Despas","doi":"10.1016/j.ctarc.2024.100801","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100801","url":null,"abstract":"<div><h3>Introduction</h3><p>Previous studies have identified an interaction between protein kinase inhibitors (PKIs) and proton pump inhibitors (PPIs) in patients with lung cancer. This type of interaction may reduce the efficacy of PKIs. However, the effect of PKI-PPI interaction on patient mortality remains controversial. This study set out to determine the impact of PKI-PPI interaction on overall survival for lung cancer patients.</p></div><div><h3>Materials and methods</h3><p>This study was conducted using data from the French National Health Care Database from January 1, 2011 to December 31, 2021. We identified patients with: (i) an age equal to or greater than 18 years; (ii) lung cancer; and (iii) at least one reimbursement for one of the following drugs: erlotinib, gefitinib, afatinib and osimertinib. Patients were followed-up between the first date of PKI reimbursement and either December 31, 2021 or if they died, the date on which death occurred. The cumulative exposure to PPI duration during PKI treatment was calculated as the ratio between the number of concomitant exposure days to PKI and PPI and the number of exposure days to PKI. A survival analysis using a Cox proportional hazards model was then performed to assess the risk of death following exposure to a PKI-PPI interaction.</p></div><div><h3>Results</h3><p>34,048 patients received at least one reimbursement for PKIs of interest in our study: 26,133 (76.8 %) were exposed to erlotinib; 3,142 (9.2 %) to gefitinib; 1,417 (4.2 %) to afatinib; and 3,356 (9.9 %) to osimertinib. Patients with concomitant exposure to PKI-PPI interaction during 20 % or more of the PKI treatment period demonstrated an increased risk of death (HR, 1.60 [95 % CI, 1.57–1.64]) compared to other patients. When this cut-off varied from 10 % to 80 %, the estimated HR ranged from 1.46 [95 % CI, 1.43–1.50] to 2.19 [95 % CI, 2.12–2.25].</p></div><div><h3>Discussion/Conclusion</h3><p>In our study, an elevated risk of death was observed in patients exposed to PKI-PPI interaction. Finally, we were able to identify a dose-dependent effect for this interaction. This deleterious effect of osimertinib and PPI was revealed for the first time in real life conditions.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100801"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000133/pdfft?md5=eee683c40bcf36dabf59631a9b1a5846&pid=1-s2.0-S2468294224000133-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140030978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB–IIIA non-small cell lung cancer in Norway–a nationwide cohort study","authors":"Åslaug Helland ,&nbsp;Tor Åge Myklebust ,&nbsp;Simona Conte ,&nbsp;Line Elmerdahl Frederiksen ,&nbsp;Jørgen Aarøe ,&nbsp;Espen Enerly","doi":"10.1016/j.ctarc.2023.100785","DOIUrl":"10.1016/j.ctarc.2023.100785","url":null,"abstract":"<div><h3>Introduction</h3><p>Testing for mutations of epidermal growth factor receptor (EGFR) is crucial to identify non-small cell lung cancer (NSCLC) patients eligible for treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs); This study aims to describe <em>EGFR</em>-mutation testing, treatment patterns, and overall survival (OS) in localized NSCLC patients.</p></div><div><h3>Materials and Methods</h3><p>Patients with localized (Stage IB–IIIA) NSCLC registered in the Norwegian Cancer Registry during 2010–2017 were followed from diagnosis until emigration, death, or end of study in 2018. The cohort was linked to data from the Norwegian Patient Registry, the Prescription Database, and the Cause of Death Registry.</p></div><div><h3>Results</h3><p>Of 2367 patients identified with localized NSCLC, 52 % were females and median age at diagnosis was 69 years. Most (66 %) were treated with surgery, while 16 % received curatively-intended radiotherapy (RT). <em>EGFR</em>-mutation testing increased significantly from 58 to 84 % during the study period. Testing frequencies varied across regions and comorbidity levels. Nine-percent of tested patients were <em>EGFR</em>-mutation positive (<em>EGFR</em>m+), of whom 27 % were treated with EGFR-TKIs. There was no correlation between initial treatment with either surgery or RT and EGFR-TKI use. The 3-year OS did not vary considerably by <em>EGFR</em>-mutation testing, but <em>EGFR</em>m+ patients had a higher 3-year OS (78.8 %) than wild-type <em>EGFR</em> (<em>EGFR</em>wt) patients (65.9 %).</p></div><div><h3>Discussion</h3><p>Although <em>EGFR</em>-mutation testing is increasingly being implemented in the early-stage setting in line with national recommendations, some patients are still not being tested for molecular markers as part of their diagnostic workup–a prerequisite for providing equal access to effective targeted treatments, such as EGFR-TKIs, to eligible patients.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"38 ","pages":"Article 100785"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294223001077/pdfft?md5=89513b842d06e6feb1903a13ceda743f&pid=1-s2.0-S2468294223001077-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139189727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of genomic profiling of Mexican women with breast cancer using EndoPredict","authors":"Diana Carolina Correa Sandoval ,&nbsp;Jose Luis Guzman Murguia ,&nbsp;Diego Alberto Guajardo Nieto","doi":"10.1016/j.ctarc.2024.100851","DOIUrl":"10.1016/j.ctarc.2024.100851","url":null,"abstract":"<div><h3>Purpose</h3><div>In the context of rising breast cancer incidence and mortality rates in Mexico, our study delves into the genomic landscape of Mexican women diagnosed with stage I-III breast cancer.</div></div><div><h3>Methods</h3><div>Employing the EndoPredict test for genomic analysis, our retrospective, cross-sectional study explores correlations between genomic expression and immunohistochemistry (IHC).</div></div><div><h3>Results</h3><div>Among 50 female patients, risk stratification by IHC revealed 50 % as high risk and 50 % as low risk, with notable clinical and histological distinctions between the two groups. High-risk samples exhibited larger tumors, higher histological grades, and more positive lymph nodes. Immunohistochemistry results displayed a moderate concordance (kappa Cohen´s 0.48) with the EndoPredict test, emphasizing its clinical reliability over IHC.</div></div><div><h3>Conclusions</h3><div>The study advocates for the integration of genomic tools, particularly the EndoPredict test, in the management of breast cancer in Mexican women for enhanced precision in treatment decisions. Our findings contribute valuable insights to the evolving landscape of breast cancer diagnosis and management in the Mexican population.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100851"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142963800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized medicine: An alternative for cancer treatment","authors":"Devendra Singh ,&nbsp;Vinay Kumar Dhiman ,&nbsp;Minakshi Pandey ,&nbsp;Vivek Kumar Dhiman ,&nbsp;Avinash Sharma ,&nbsp;Himanshu Pandey ,&nbsp;Sunil Kumar Verma ,&nbsp;Rajeev Pandey","doi":"10.1016/j.ctarc.2024.100860","DOIUrl":"10.1016/j.ctarc.2024.100860","url":null,"abstract":"<div><div>The incidence of cancer continues to increase worldwide, resulting in significant physical, emotional, and financial challenges for individuals, families, communities, and healthcare systems. Cancer is projected to be responsible for approximately 10 million deaths in 2020, accounting for one in six deaths globally. Prostate, colon, lung, and breast cancers are the most common types of cancer. In India, it is estimated that there will be around 2.7 million cancer patients by 2020. Personalized medicine has the potential to offer an alternative approach to cancer treatment. Precision medicine, often known as personalized medicine, is a new cancer treatment technique that focuses on tailoring medication to each patient's specific genetic, biochemical, and lifestyle factors. The goal is to optimize tumor response while minimizing therapy side effects, resulting in improved patient care and quality of life. Personalized medicine allows for the creation of focused medicines that address specific gene mutations by leveraging knowledge about a patient's cancer, including its genetic makeup. Ongoing research seeks to detect gene modifications in diverse cancer types, produce novel diagnostic tools, and develop treatments that particularly target these genetic changes. In recent years, personalized medicine has achieved major advances in the treatment of solid tumors, with the promise to improve treatment precision, reduce side effects, as well as enhance outcomes for patients in cancer therapy. This review aims to objectively evaluate the transformation of cancer treatment, emphasizing the shift towards a more precise methodology.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100860"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies","authors":"Ying Liu ,&nbsp;Lin Wu ,&nbsp;Dingzhi Huang ,&nbsp;Qiming Wang ,&nbsp;Chen Yang ,&nbsp;Li Zhou ,&nbsp;Shuguang Sun ,&nbsp;Xiaomei Jiang ,&nbsp;Ying Cheng","doi":"10.1016/j.ctarc.2025.100869","DOIUrl":"10.1016/j.ctarc.2025.100869","url":null,"abstract":"<div><h3>Background</h3><div>Trilaciclib is a transient cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that reduces the incidence of chemotherapy-induced myelosuppression (CIM). In this pooled analysis, we evaluated the multilineage myeloprotection, antitumor efficacy, and safety of trilaciclib treatment in patients with extensive-stage small-cell lung cancer (ES-SCLC). Moreover, myeloprotection effect in 1 L, 2 L/3 L population and effect by risk category were explored.</div></div><div><h3>Materials and Methods</h3><div>Patients with ES-SCLC who received trilaciclib were included. Trilaciclib was administered before chemotherapy in four randomized, double-blind, placebo-controlled studies (NCT02499770, NCT03041311, NCT02514447, and NCT04902885), and data were subsequently extracted. The primary endpoints were the duration of severe neutropenia (DSN) in cycle 1 and/or the incidence of severe neutropenia (SN).</div></div><div><h3>Results</h3><div>The data from 325 patients receiving trilaciclib (<em>n</em> = 164) or placebo (<em>n</em> = 161) were pooled. Trilaciclib demonstrated a clinically and statistically significant reduction in DSN in cycle 1 and in the incidence of SN and febrile neutropenia (FN) in the overall, 1 L, 2 L/3 L populations. The myeloprotection effect was greater in patients with a higher number of FN risk categories. Overall, the median progression-free survival was 5.3 months in the trilaciclib and 4.9 months in the placebo group. The median overall survival was 10.9 months in the trilaciclib and 10.1 months in the placebo group. Trilaciclib showed better capability of reducing CIMs incidence compared with prophylactic G-CSF in the overall and 1 L population.</div></div><div><h3>Conclusions</h3><div>Trilaciclib prior to chemotherapy in patients with ES-SCLC reduced incidence of CIM and need for supportive care in CIM across all treatment settings.</div></div><div><h3>Micro Abstract</h3><div>Area and reason for the study: Extensive-stage small-cell lung cancer (ES-SCLC). To analyze the effect of trilaciclib on Chinese and Caucasian patients. Approach taken, including aspects such as the sample size: This pooled analysis included one study in China and three studies in western countries, and the overall sample size was 325. Overall result: Trilaciclib provides protection from CIM. General significance of the findings: The consistent efficacy of trilaciclib can be observed from pooled data across different treatment lines. All information should be accessible to a nonexpert audience.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100869"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized controlled trial: Effects of compression therapy combined with exercise on chemotherapy-induced peripheral neuropathy in patients with breast cancer","authors":"Yu Xiaoqian ,&nbsp;Hu Jiwei ,&nbsp;Zhou Lizhi ,&nbsp;Guo Baojia ,&nbsp;Guo Luyan ,&nbsp;Xu Huiqian ,&nbsp;Li Hong ,&nbsp;Fan Yijing","doi":"10.1016/j.ctarc.2025.100871","DOIUrl":"10.1016/j.ctarc.2025.100871","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the effects of compression therapy combined with exercise for cancer patients (EXCAP) in patients with peripheral neuropathy caused by breast cancer chemotherapy.</div></div><div><h3>Methods</h3><div>Overall, 108 patients with peripheral neuropathy after chemotherapy for breast cancer were randomly divided into the control group (routine nursing), experimental group 1 (compression therapy), and experimental group 2 (compression therapy and EXCAP). The National Institute of Cancer Drug Toxicity Rating Scale and the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool were assessed and compared between groups.</div></div><div><h3>Results</h3><div>The incidence of grade 0 peripheral neuropathy in both experimental groups was higher than that in controls (<em>P</em> &lt; 0.001), and the incidence in group 2 was higher than that in group 1 (<em>P</em> &lt; 0.001). The incidence of grade 2 disease in both experimental groups was lower than that in controls (<em>P</em> &lt; 0.001). The rate of symptoms in both experimental groups after the intervention were lower than that in the control group (<em>P</em> &lt; 0.001), and those in experimental group 2 were lower than those in experimental group 1 (<em>P</em> &lt; 0.001). Scores regarding activities of daily living in the experimental groups were lower than those of the control group (<em>P</em> &lt; 0.001), and lower in group 2 than in group 1 (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Compression therapy and EXCAP can effectively reduce the incidence of chemotherapy-induced peripheral neuropathy in patients undergoing breast cancer chemotherapy. They can both positively impact patients' daily lives and symptom experiences; however, they are more effective when combined.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100871"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy","authors":"Sajjad Ahmadpour ,&nbsp;Mohammad Amin Habibi ,&nbsp;Farzaneh Sadat Ghazi ,&nbsp;Mikaeil Molazadeh ,&nbsp;Mohammad Reza Pashaie ,&nbsp;Yousef Mohammadpour","doi":"10.1016/j.ctarc.2024.100823","DOIUrl":"10.1016/j.ctarc.2024.100823","url":null,"abstract":"<div><p>Tumors can produce bioactive substances called tumor-derived supernatants (TDS) that modify the immune response in the host body. This can result in immunosuppressive effects that promote the growth and spread of cancer. During tumorigenesis, the exudation of these substances can disrupt the function of immune sentinels in the host and reinforce the support for cancer cell growth. Tumor cells produce cytokines, growth factors, and proteins, which contribute to the progression of the tumor and the formation of premetastatic niches. By understanding how cancer cells influence the host immune system through the secretion of these factors, we can gain new insights into cancer diagnosis and therapy.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100823"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000352/pdfft?md5=50a6996ac4bc66271d4187b169d09594&pid=1-s2.0-S2468294224000352-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141278925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance","authors":"Chenming Zheng,&nbsp;Kavita Y. Sarin","doi":"10.1016/j.ctarc.2024.100837","DOIUrl":"10.1016/j.ctarc.2024.100837","url":null,"abstract":"<div><p>The multifactorial etiology underlying melanoma development involves an array of genetic, phenotypic, and environmental factors. Genetic predisposition for melanoma is further influenced by the complex interplay between high-, medium-, and low-penetrance genes, each contributing to varying degrees of susceptibility. Within this network, high-penetrance genes, including <em>CDKN2A, CDK4, BAP1</em>, and <em>POT1,</em> are linked to a pronounced risk for disease, whereas medium- and low-penetrance genes, such as <em>MC1R, MITF</em>, and others, contribute only moderately to melanoma risk. Notably, these genetic factors not only heighten the risk of melanoma but may also increase susceptibility towards internal malignancies, such as pancreatic cancer, renal cell cancer, or neural tumors. Genetic testing and counseling hold paramount importance in the clinical context of suspected hereditary melanoma, facilitating risk assessment, personalized surveillance strategies, and informed decision-making. As our understanding of the genomic landscape deepens, this review paper aims to comprehensively summarize the genetic underpinnings of hereditary melanoma, as well as current screening and management strategies for the disease.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100837"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000492/pdfft?md5=9f10c8ce18e2ed33ecd14aa1c68588fa&pid=1-s2.0-S2468294224000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment","authors":"Saki Tanaka ,&nbsp;Motohiro Tamiya ,&nbsp;Satoshi Nishiuma ,&nbsp;Sayaka Nakamura ,&nbsp;Keisuke Nozaki ,&nbsp;Naoko Watanabe ,&nbsp;Chisae Itoh ,&nbsp;Yukio Kadokawa ,&nbsp;Kenji Takeda ,&nbsp;Kozo Takahashi ,&nbsp;Akito Miyazaki ,&nbsp;Takahisa Kawamura ,&nbsp;Kei Kunimasa ,&nbsp;Takako Inoue ,&nbsp;Kazumi Nishino ,&nbsp;Mari Takagi","doi":"10.1016/j.ctarc.2024.100836","DOIUrl":"10.1016/j.ctarc.2024.100836","url":null,"abstract":"<div><h3>Background</h3><p>The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however some patients withdraw or reduce the dosage due to adverse events (AEs).</p></div><div><h3>Methods</h3><p>We performed a retrospective cohort study of 98 patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who received 80 mg osimertinib as the initial treatment. We investigated the impact of BSA on efficacy and safety of osimertinib.</p></div><div><h3>Results</h3><p>The cut-off value of BSA was estimated using the receiver operating characteristics curve, and was determined to be 1.5 m². There were 44 patients in the BSA &lt; 1.5 group and 54 patients in the BSA ≥ 1.5 group. There was no significant difference in the incidence of AEs (hematologic toxicity of ≥grade 3 or higher, and non-hematologic toxicity of ≥grade 3) between the two groups. However, the incidence of dose reduction due to AEs was significantly higher in the BSA &lt; 1.5 group compared with the BSA ≥ 1.5 group (16 patients vs 5 patients, <em>p</em> = 0.003). The main reasons were fatigue, anorexia, diarrhea, and liver disfunction. Median progression-free survival (PFS) was not significantly different (16.9 months in the BSA &lt; 1.5 group vs 18.1 months in the BSA ≥ 1.5 group, <em>p</em> = 0.869).</p></div><div><h3>Conclusion</h3><p>Differences in BSA affected the optimal dose of osimertinib. However, the PFS with osimertinib treatment was not affected by BSA. Therefore, when using osimertinib as an initial treatment for patients with EGFR-mutant NSCLC, dose reduction to control AEs should be considered, especially in the BSA&lt;1.5 group.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100836"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000480/pdfft?md5=9618c1dc15ff3738502bc6dd4ff016f7&pid=1-s2.0-S2468294224000480-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of neoadjuvant chemotherapy in pregnancy with cervical cancer (IB3)","authors":"Xiaohua Li ,&nbsp;Yu Zhang ,&nbsp;Haiying Wu ,&nbsp;Shaoqiong Li ,&nbsp;Shuxian Ge ,&nbsp;Jian Gao","doi":"10.1016/j.ctarc.2023.100749","DOIUrl":"10.1016/j.ctarc.2023.100749","url":null,"abstract":"<div><p>Compared with the early symptoms of non-pregnancy, the early pregnancy with cervical cancer is often confused with threatened abortion, so it is difficult to diagnose and delay the time of treatment. At present, compared with cervical cancer, there is no clear and standard treatment for cervical cancer in pregnancy. At present, the diagnosis and treatment plan is mainly made according to the pathological examination, staging, fetal development (whether there is abnormality on ultrasound and whether the chromosome karyotype is normal or not) and the pregnant women and their family members’ pregnancy wishes. A case of pregnancy complicated with cervical cancer who was terminated by planned cesarean section after neoadjuvant chemotherapy (NACT) with irregular vaginal bleeding as the first symptom was analyzed retrospectively.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"38 ","pages":"Article 100749"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294223000710/pdfft?md5=f9b40e7d3b275a37f39006f987756fb8&pid=1-s2.0-S2468294223000710-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48065102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}